default author photo

Nyaradzo M. Mgodi

University of Zimbabwe - Clinical Trials Research Centre

Harare

Zimbabwe

SCHOLARLY PAPERS

3

DOWNLOADS

220

TOTAL CITATIONS

0

Scholarly Papers (3)

1.

Cabotegravir for Prevention of HIV-1 in Women: Results From HPTN 084, a Phase III, Randomised Controlled Trial

THELANCET-D-22-01258
Number of pages: 186 Posted: 25 Mar 2022
University of the Witwatersrand - Reproductive Health and HIV Research Unit (RHRU), Fred Hutchinson Cancer Research Center - Vaccine and Infectious Disease Division, Stellenbosch University, Kenya Medical Research Institute (KEMRI), CeSHHAR Zimbabwe, South African Medical Research Council - HIV Prevention and Vaccine Research Unit, Blantyre International University, Botswana Harvard AIDS Institute Partnership (BHP), University of Zimbabwe - Clinical Trials Research Centre, University of the Witwatersrand, South African Medical Research Council - HIV Prevention and Vaccine Research Unit, Government of Uganda - Uganda Virus Research Institute (UVRI), University of Zimbabwe - Clinical Trials Research Centre, University of Zimbabwe - Clinical Trials Research Centre, Baylor University - Children’s Foundation-Eswatini, University of Cape Town (UCT) - Desmond Tutu HIV Centre, Makerere University, Columbia University - ICAP, Chris Hani Baragwanath Academic Hospital - Perinatal HIV Research Unit, South African Medical Research Council - HIV Prevention and Vaccine Research Unit, University of Zimbabwe - Clinical Trials Research Centre, FHI 360, FHI 360, University of the Witwatersrand, University of Colorado, Aurora - Anschutz Medical Campus, Johns Hopkins University - Department of Pathology, Johns Hopkins University - Department of Pathology, Johns Hopkins University - School of Medicine, Johns Hopkins University - Department of Pathology, Johns Hopkins University - School of Medicine, FHI 360, University of the Witwatersrand - Faculty of Health Sciences, University of the Witwatersrand, Johns Hopkins University - School of Medicine, Fred Hutchinson Cancer Research Center - Statistical Center for HIV/AIDS Research and Prevention, Fred Hutchinson Cancer Research Center - Statistical Center for HIV/AIDS Research and Prevention, FHI 360, FHI 360, Stroger Hospital of Cook County, FHI 360, FHI 360, Government of the United States of America - National Institute of Allergy and Infectious Diseases (NIAID), Government of the United States of America - National Institute of Allergy and Infectious Diseases (NIAID), Gilead Sciences, ViiV Healthcare Ltd., ViiV Healthcare Ltd., ViiV Healthcare Ltd., Fred Hutchinson Cancer Research Center - Statistical Center for HIV/AIDS Research and Prevention, University of North Carolina (UNC) at Chapel Hill, University of North Carolina (UNC) at Chapel Hill - UNC-Project Malawi and affiliation not provided to SSRN
Downloads 112 (635,507)

Abstract:

Loading...

2.

Impact of Catch-Up Human Papillomavirus Vaccination on Cervical Cancer Incidence in Kenya: A Mathematical Modeling Evaluation of HPV Vaccination Strategies in the Context of Moderate HIV Prevalence

Number of pages: 26 Posted: 04 Oct 2021
University of Washington - Department of Global Health, University of Washington - Department of Global Health, University of Washington - Department of Global Health, Bill & Melinda Gates Foundation, Kenya Medical Research Institute (KEMRI), University of Zimbabwe - Clinical Trials Research Centre, University of Zimbabwe - Faculty of Medicine and Health Sciences, Kenya Medical Research Institute (KEMRI), Creighton University - School of Medicine, University of California, San Francisco (UCSF) - Department of Obstetrics, Gynecology & Reproductive Sciences and Division of Allergy and Infectious Diseases, University of Washington
Downloads 62 (951,658)

Abstract:

Loading...

HPV vaccination, HIV, cervical cancer, mathematical model, HPV

3.

Infusion Reactions in Persons Receiving the Broadly Neutralizing Antibody VRC01 or Placebo for Reduction of HIV-1 Acquisition: Results From the Phase 2b Antibody Mediated Prevention (AMP) Randomized Trials

Number of pages: 30 Posted: 14 May 2021
Fred Hutchinson Cancer Research Center, Fred Hutchinson Cancer Research Center - Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Research Center - Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Research Center, Emory University - School of Medicine, Fred Hutchinson Cancer Research Center, Fred Hutchinson Cancer Research Center, National Institutes of Health - Vaccine Research Center, Botswana Harvard AIDS Institute Partnership (BHP), University of Cape Town (UCT) - Institute of Infectious Disease and Molecular Medicine, South African Medical Research Council, Asociacion Civil Impacta Salud y Educacion, - Instituto Nacional de Infectologia Evandro Chagas (INIEC), Harvard University - Brigham and Women’s Hospital, FHI 360 (Family Health International), Fred Hutchinson Cancer Research Center, Fred Hutchinson Cancer Research Center - Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Research Center - Vaccine and Infectious Disease Division, Government of the United States of America - National Institutes of Health (NIH), Government of the United States of America - National Institutes of Health (NIH), Government of the United States of America - National Institutes of Health (NIH), Government of the United States of America - National Institutes of Health (NIH), University of North Carolina (UNC) at Chapel Hill - Department of Medicine, Fred Hutchinson Cancer Research Center, Aurum Institute and University of Zimbabwe - Clinical Trials Research Centre
Downloads 46 (1,109,210)

Abstract:

Loading...

infusion related reactions, hypersensitivity, broadly neutralizing antibodies, AMP study, HIV